Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Ivacaftor/lumacaftor

Tiredness, respiratory worsening of cystic fibrosis and elevation of AST and ALT: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Zwitserloot AM, et al. Real-life data of lumacaftor/ivacaftor therapy in children with cystic fibrosis homozygous for F508del with emphasis on small airway disease in the Netherlands. Journal of Cystic Fibrosis 22 (Suppl. 2): S83 (plus poster) abstr. P067, Jun 2023. Available from: URL: http://doi.org/10.1016/S1569-1993%2823%2900442-3 [abstract] Zwitserloot AM, et al. Real-life data of lumacaftor/ivacaftor therapy in children with cystic fibrosis homozygous for F508del with emphasis on small airway disease in the Netherlands. Journal of Cystic Fibrosis 22 (Suppl. 2): S83 (plus poster) abstr. P067, Jun 2023. Available from: URL: http://​doi.​org/​10.​1016/​S1569-1993%2823%2900442-3 [abstract]
Metadaten
Titel
Ivacaftor/lumacaftor
Tiredness, respiratory worsening of cystic fibrosis and elevation of AST and ALT: 3 case reports
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-42363-4

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Pembrolizumab

Case report

Capecitabine

Case report

Antineoplastics